SG11201806538WA - Engineered antigen presenting cells and uses thereof - Google Patents

Engineered antigen presenting cells and uses thereof

Info

Publication number
SG11201806538WA
SG11201806538WA SG11201806538WA SG11201806538WA SG11201806538WA SG 11201806538W A SG11201806538W A SG 11201806538WA SG 11201806538W A SG11201806538W A SG 11201806538WA SG 11201806538W A SG11201806538W A SG 11201806538WA SG 11201806538W A SG11201806538W A SG 11201806538WA
Authority
SG
Singapore
Prior art keywords
international
rule
epfl
lausanne
pct
Prior art date
Application number
SG11201806538WA
Inventor
Palma Michele De
Mario Leonardo Squadrito
Original Assignee
Ecole Polytechnique Fed Lausanne Epfl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ecole Polytechnique Fed Lausanne Epfl filed Critical Ecole Polytechnique Fed Lausanne Epfl
Publication of SG11201806538WA publication Critical patent/SG11201806538WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464469—Tumor associated carbohydrates
    • A61K39/464471—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 111111110111101110101011111010111110111011111111101011101101111101111011111 International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... .....!;,' WO 2017/134100 Al 10 August 2017(10.08.2017) WIPO I PCT (51) International Patent Classification: KP, C07K 14/705 (2006.01) A61K 39/00 (2006.01) MD, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, C07K 16/32 (2006.01) NI, RU, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (21) International Application Number: TH, PCT/EP2017/052145 ZA, ZM, ZW. TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (22) International Filing Date: (84) Designated States (unless otherwise indicated, for every 1 February 2017 (01.02.2017) kind of regional protection available): ARIPO (BW, GH, (25) Filing Language: English GM, TZ, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (26) Publication Language: English TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (30) Priority Data: DK, 16153966.3 2 February 2016 (02.02.2016) EP LV, SM, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (71) Applicant: ECOLE POLYTECHNIQUE FEDERALE GW, KM, ML, MR, NE, SN, TD, TG). DE LAUSANNE (EPFL) [CH/CH]; EPFL-TTO, EPFL Innovation Park J, CH-1015 Lausanne (CH). Declarations under Rule 4.17: (72) Inventors: DE PALMA, Michele; Rue du Petit St-Jean 5, as to applicant's entitlement to apply for and be granted a 1003 Lausanne (CH). SQUADRITO, Mario Leonardo; patent (Rule 4.17(u)) Chemin de Belle Vue 14, 1020 Renens (CH). — as to the applicant's entitlement to claim the priority of the _ earlier application (Rule 4.17(iii)) Agent: REUTELER & CIE SA; Chemin de la Vuarpil- (74) here 29, CH-1260 Nyon (CH). — of inventorship (Rule 4.17(iv)) Designated States (unless otherwise indicated, for every Published: (81) = kind of national protection available): AE, AG, AL, AM, _ with international search report (Art. 21(3)) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, — with DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, sequence listing part of description (Rule 5.2(a)) = = = = = = = = = 1-1 © © Il 7r M Il IN 1-1 (54) Title: ENGINEERED ANTIGEN PRESENTING CELLS AND USES THEREOF 0 ei (57) : The present invention relates to engineered extra-cellular vesicle internalizing receptors that have the ability to en- hance uptake, processing, and presentation to T-cells of tumor-associated antigens by an antigen-presenting cell. It further relates to vectors or antigen presenting cells expressing said receptors, composition and uses thereof for the prevention and/or treatment of a cancer.
SG11201806538WA 2016-02-02 2017-02-01 Engineered antigen presenting cells and uses thereof SG11201806538WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16153966.3A EP3202783A1 (en) 2016-02-02 2016-02-02 Engineered antigen presenting cells and uses thereof
PCT/EP2017/052145 WO2017134100A1 (en) 2016-02-02 2017-02-01 Engineered antigen presenting cells and uses thereof

Publications (1)

Publication Number Publication Date
SG11201806538WA true SG11201806538WA (en) 2018-08-30

Family

ID=55310688

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806538WA SG11201806538WA (en) 2016-02-02 2017-02-01 Engineered antigen presenting cells and uses thereof

Country Status (11)

Country Link
US (1) US11591407B2 (en)
EP (2) EP3202783A1 (en)
JP (1) JP6989523B2 (en)
KR (1) KR20180104146A (en)
CN (1) CN108602873A (en)
AU (1) AU2017216213B2 (en)
CA (1) CA3012574A1 (en)
IL (1) IL260905B1 (en)
MX (1) MX2018009312A (en)
SG (1) SG11201806538WA (en)
WO (1) WO2017134100A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
CN112218621A (en) * 2018-04-10 2021-01-12 西北大学 Extracellular vesicles comprising a targeting affinity domain based membrane protein
CN110612117B (en) * 2018-04-17 2024-04-12 分子模板公司 HER2 targeting molecules comprising deimmunized shiga toxin a subunit scaffolds
WO2020097193A1 (en) 2018-11-06 2020-05-14 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
CN114173807B (en) * 2019-09-02 2024-03-19 庆北大学校产学协力团 Composition for preventing or treating cancer comprising IL-2 surface expression-extracellular vesicles as active ingredients
JP2022546592A (en) 2019-09-03 2022-11-04 マイエロイド・セラピューティクス，インコーポレーテッド Methods and compositions for genomic integration
CA3153311A1 (en) * 2019-09-06 2021-03-11 The Regents Of The University Of California Chimeric antigen receptors and related methods and compositions for the treatment of cancer
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
WO2021127024A1 (en) * 2019-12-16 2021-06-24 Washington University Chimeric antigen receptor dendritic cells (car-dcs) and methods of making and using same
CN113106067A (en) * 2020-01-10 2021-07-13 南京大学 Construction and application of chimeric antigen receptor-monocyte/macrophage (CAR-M)
AU2021376354A1 (en) 2020-11-04 2023-06-22 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
US20230071148A1 (en) * 2021-07-15 2023-03-09 Vcreate, Inc. Compositions and Methods for Making Novel T-Cell Receptors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004012817A2 (en) * 2002-07-31 2004-02-12 Kylix B.V. Use of genes identified to be involved in tumor development for the development of anti-cancer drugs
US20060134109A1 (en) * 2002-09-09 2006-06-22 Nura Inc. G protein coupled receptors and uses thereof
US8211852B2 (en) * 2006-02-17 2012-07-03 Rappaport Family Institute For Research In The Medical Sciences Molecules and methods of using same for treating CCR5/CCR5 ligands associated diseases
JP2010531666A (en) * 2007-06-26 2010-09-30 ユニバーシティ オブ マイアミ Antibody-endostatin fusion protein and variants thereof
US8273550B2 (en) 2007-10-25 2012-09-25 Viventia Biotechnologies Inc. Antibodies against a cancer-associated epitope of variant HnRNPG and uses thereof
AU2008329518A1 (en) 2007-11-27 2009-06-04 Viventia Biotechnologies Inc. Antibodies against a cancer-associated epitope of variant NFKBIB and uses thereof
US20110158995A1 (en) * 2008-07-28 2011-06-30 Renault S.A.S Multi-Specific Binding Proteins Targeting B Cell Disorders
EA032828B1 (en) * 2008-10-10 2019-07-31 Аптево Рисёрч Энд Девелопмент Ллс Tcr complex immunotherapeutics
WO2010117448A2 (en) * 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
TWI507204B (en) 2009-05-26 2015-11-11 Oncotherapy Science Inc Cdc45l peptides and vaccines including the same
US10093740B2 (en) * 2012-10-15 2018-10-09 Universitat Zurich Bispecific HER2 ligands for cancer therapy
EP2777711A1 (en) * 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
US10239948B2 (en) * 2013-12-20 2019-03-26 Cellectis Method of engineering multi-input signal sensitive T cell for immunotherapy
CN106536558A (en) * 2014-04-10 2017-03-22 西雅图儿童医院（Dba西雅图儿童研究所） Transgene genetic tags and methods of use
GB201410262D0 (en) * 2014-06-10 2014-07-23 Cambridge Entpr Ltd Novel method
JP2018504143A (en) * 2015-01-26 2018-02-15 セレクティスＣｅｌｌｅｃｔｉｓ Anti-HSP70-specific chimeric antigen receptor (CAR) for cancer immunotherapy

Also Published As

Publication number Publication date
US11591407B2 (en) 2023-02-28
JP2019511244A (en) 2019-04-25
MX2018009312A (en) 2019-01-28
AU2017216213A1 (en) 2018-09-20
CN108602873A (en) 2018-09-28
US20190062450A1 (en) 2019-02-28
IL260905B1 (en) 2024-01-01
EP3411394A1 (en) 2018-12-12
CA3012574A1 (en) 2017-08-10
WO2017134100A1 (en) 2017-08-10
KR20180104146A (en) 2018-09-19
JP6989523B2 (en) 2022-01-05
AU2017216213B2 (en) 2021-07-01
EP3202783A1 (en) 2017-08-09
IL260905A (en) 2018-09-20

Similar Documents

Publication Publication Date Title
SG11201806538WA (en) Engineered antigen presenting cells and uses thereof
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201908023YA (en) T cell receptors and immune therapy using the same against prame positive cancers
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201806905UA (en) Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201804134YA (en) Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
SG11201808125RA (en) Methods for solid tumor treatment
SG11201805950UA (en) Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201408746XA (en) Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
SG11201907927SA (en) Binding molecules that specifically bind to tau
SG11201805001UA (en) Method of treating influenza a
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201809594WA (en) Nicotine particles and compositions
SG11201807677YA (en) Antibodies to cd40 with enhanced agonist activity
SG11202000494UA (en) Drug delivery composition
SG11201908275XA (en) Peptides and methods for the treatment of diabetes
SG11201804704PA (en) Compositions and methods for decreasing tau expression